Oncology

The nasal antidepressant of Johnson & Johnson leads to FDA committee The antidepressant esketamine of Johnson & Johnson heads to FDA panel. This might be an end for the discoveries in novel therapies for the disorder. The intranasal, esketamine would be one of the first new approaches to treat the refractory major depressive disorder (MDD) if FDA gives a nod to it. This would provide a new alternative for people, who could not control symptoms though after receiving drug therapy. New small cell lung cancer model discloses vital role of two mutated genes Small cell lung cancer (SCLC) develops in people who smoke often and it becomes resistant to chemo...